| Non–small cell lung cancer DS Ettinger, W Akerley, G Bepler, MG Blum, A Chang, RT Cheney, ... Journal of the national comprehensive cancer network 8 (7), 740-801, 2010 | 1137* | 2010 |
| Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases KE Rusthoven, BD Kavanagh, H Cardenes, VW Stieber, SH Burri, ... Journal of Clinical Oncology 27 (10), 1572-1578, 2009 | 978 | 2009 |
| Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines WJ Scott, J Howington, S Feigenberg, B Movsas, K Pisters Chest 132 (3), 234S-242S, 2007 | 766 | 2007 |
| Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer A Pollack, G Walker, EM Horwitz, R Price, S Feigenberg, AA Konski, ... Journal of Clinical Oncology 31 (31), 3860-3868, 2013 | 539 | 2013 |
| Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial A Pollack, AL Hanlon, EM Horwitz, SJ Feigenberg, AA Konski, B Movsas, ... International Journal of Radiation Oncology* Biology* Physics 64 (2), 518-526, 2006 | 296 | 2006 |
| Angiosarcoma after breast‐conserving therapy AT Monroe, SJ Feigenberg, NP Mendenhall Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 252 | 2003 |
| Increasing national mastectomy rates for the treatment of early stage breast cancer U Mahmood, AL Hanlon, M Koshy, R Buras, S Chumsri, KH Tkaczuk, ... Annals of surgical oncology 20, 1436-1443, 2013 | 217 | 2013 |
| Spatial-temporal [18F] FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy S Tan, S Kligerman, W Chen, M Lu, G Kim, S Feigenberg, WD D'Souza, ... International Journal of Radiation Oncology* Biology* Physics 85 (5), 1375-1382, 2013 | 178 | 2013 |
| Prostate cancer radiotherapy dose response: an update of the fox chase experience A Pollack, AL Hanlon, EM Horwitz, SJ Feigenberg, RG Uzzo, GE Hanks The Journal of urology 171 (3), 1132-1136, 2004 | 172 | 2004 |
| Radiation therapy for giant cell tumors of bone SJ Feigenberg, RB Marcus, RA Zlotecki, MT Scarborough, BH Berrey, ... Clinical Orthopaedics and Related Research® 411, 207-216, 2003 | 167 | 2003 |
| Head and neck tumors JA Ridge, BS Glisson, MN Lango, S Feigenberg, E Horwitz Cancer management: a multidisciplinary approach 11 (3), 369, 2008 | 147 | 2008 |
| Consensus statement on proton therapy in early-stage and locally advanced non–small cell lung cancer JY Chang, SK Jabbour, D De Ruysscher, SE Schild, CB Simone II, ... International Journal of Radiation Oncology* Biology* Physics 95 (1), 505-516, 2016 | 141 | 2016 |
| A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy DB Chism, AL Hanlon, EM Horwitz, SJ Feigenberg, A Pollack International Journal of Radiation Oncology* Biology* Physics 59 (2), 380-385, 2004 | 141 | 2004 |
| Megavoltage radiotherapy for aneurysmal bone cysts SJ Feigenberg, RB Marcus Jr, RA Zlotecki, MT Scarborough, BH Berrey, ... International Journal of Radiation Oncology* Biology* Physics 49 (5), 1243-1247, 2001 | 130 | 2001 |
| Phase 1 trial of Pembrolizumab administered concurrently with Chemoradiotherapy for locally advanced non–small cell lung cancer: a nonrandomized controlled trial SK Jabbour, AT Berman, RH Decker, Y Lin, SJ Feigenberg, SN Gettinger, ... JAMA oncology 6 (6), 848-855, 2020 | 123 | 2020 |
| Neutrophil‐lymphocyte ratio is a prognostic marker in patients with locally advanced (Stage IIIA and IIIB) non‐small cell lung cancer treated with combined modality therapy KA Scilla, SM Bentzen, VK Lam, P Mohindra, EM Nichols, MA Vyfhuis, ... The oncologist 22 (6), 737-742, 2017 | 122 | 2017 |
| Angiosarcoma after breast-conserving therapy: experience with hyperfractionated radiotherapy SJ Feigenberg, NP Mendenhall, JD Reith, JR Ward, EM Copeland III International Journal of Radiation Oncology* Biology* Physics 52 (3), 620-626, 2002 | 111 | 2002 |
| Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage L Wang, S Hayes, K Paskalev, L Jin, MK Buyyounouski, CCM Ma, ... Radiotherapy and Oncology 91 (3), 314-324, 2009 | 100 | 2009 |
| Radiation therapy dose escalation for prostate cancer: a rationale for IMRT A Pollack, A Hanlon, EM Horwitz, S Feigenberg, RG Uzzo, RA Price World journal of urology 21, 200-208, 2003 | 100 | 2003 |
| Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer A Konski, D Watkins-Bruner, S Feigenberg, A Hanlon, S Kulkarni, JR Beck, ... International Journal of Radiation Oncology* Biology* Physics 66 (2), 408-415, 2006 | 99 | 2006 |
Mark BuyyounouskiStanford UniversityVerified email at stanford.edu
